This three-wave syndicated report series tracks the introduction of Darzalex, a human anti-CD38 MAb, and Empliciti, a humanized anti-SLAMF7 MAb. The FDA approved these agents in November 2015 for relapsed/refractory multiple myeloma. This report series is based on primary research data collected at one month, three months, and one year postcommercial availability of Darzalex and Empliciti. Along with awareness and sources of familiarity, the report assesses U.S. hematological oncologists’ trial, adoption, and use of these agents, including anticipated future trends. The report provides information on product perception, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Johnson & Johnson/Janssen’s and Bristol-Myers Squibb’s promotional efforts, and benchmarking against other agents for multiple myeloma.

Table of contents

  • Darzalex/Empliciti Launch Tracking Wave 1 (US)
    • Key Findings
      • Who Is the Darzalex/Empliciti Patient?
      • Who Is the Darzalex Prescriber?
      • Who Is the Empliciti Prescriber?
      • Trends & Multiple Myeloma Market
        • Wave 1 Uptake of Darzalex and Empliciti in the Relapsed/Refractory Settings
        • Expert Opinion
    • Benchmarking Darzalex Empliciti Launch Success vs. Other Recently Launched Oncology Therapies
    • Prescriber and Nonprescriber Profiles
      • Darzalex: Differences Between Prescriber and Nonprescriber Profiles
      • Empliciti: Differences Between Prescriber and Nonprescriber Profiles
    • Darzalex Empliciti Awareness and Perceptions
      • Unaided and Aided Awareness of Darzalex Empliciti
        • Unaided Awareness of Drugs for the Treatment of Multiple Myeloma
        • Awareness and Level of Familiarity with New Multiple Myeloma Treatments
      • Familiarity with Darzalex Empliciti
        • Familiarity with Current Multiple Myeloma Treatments
        • Physician Perception of Darzalex's Approved Populations
        • Physician Perception of Empliciti's Approved Populations
        • Perceived Price of Darzalex and Empliciti
      • Sources of Familiarity with Darzalex Empliciti
        • Sources of Familiarity
      • Initial Reaction to and Interest in Darzalex Empliciti
        • Initial Reaction to Darzalex and Empliciti
      • Impressions of Darzalex and Empliciti
        • Interest in Darzalex and Empliciti
        • Uniqueness of Darzalex and Empliciti
        • Perceived Advantages of Darzalex and Empliciti
        • Perceived Disadvantages of Darzalex and Empliciti
        • Interviewed Physicians' Perceived Advantages of Darzalex and Empliciti
      • Prescriber and Nonprescriber Profiles
        • Darzalex: Differences Between Prescriber and Nonprescriber Profiles
        • Empliciti: Differences Between Prescriber and Nonprescriber Profiles
    • Darzalex Empliciti Trial and Use
      • Willingness to Prescribe Darzalex Empliciti
        • Level of Willingness to Prescribe
      • Number of Patients Currently Receiving Darzalex Empliciti
        • Prescription of Darzalex and Empliciti
        • Darzalex Discontinuation Rate Among Prescribers
        • Empliciti Discontinuation Rate Among Prescribers
        • Adverse Event Occurrence with Darzalex and Empliciti
        • Prescription of Darzalex Off-Label
        • Prescription of Empliciti Off-Label
        • Prescription of Darzalex and Empliciti by Line of Therapy
        • Patient Share by Line of Therapy
        • Impact of Darzalex's Availability on Prescribing of Other Agents
        • Impact of Empliciti's Availability on Prescribing of Other Agents
      • Reasons for Not Yet Prescribing Darzalex Empliciti
        • Main Barriers to Prescribing Darzalex and Empliciti
        • Factors Deterring Hematological Oncologists from Prescribing Darzalex in Approved Settings
        • Factors Deterring Hematological Oncologists from Prescribing Empliciti in Approved Settings
      • Anticipated Darzalex Empliciti Use
        • Most Likely Therapies to Prescribe in Each Line of Multiple Myeloma Therapy
        • Anticipated Prescribing of Darzalex and Empliciti for Previously Treated Multiple Myeloma
        • Potential Displacement of Existing Multiple Myeloma Treatments by Darzalex and Empliciti
      • Darzalex Empliciti Performance on Key Attributes
        • Importance of Attributes in Influencing Choice of Therapy
        • Risk/Benefit Perception of Darzalex and Empliciti
        • Overall Satisfaction with Darzalex and Empliciti
        • Performance of Darzalex and Empliciti on Attributes
        • Performance on Attributes: Best Agent
        • Satisfaction with Efficacy of Darzalex and Empliciti
        • Satisfaction with Safety and Tolerability of Darzalex and Empliciti
    • Effectiveness of Face-to-Face Detailing for Darzalex Empliciti
      • Darzalex Empliciti Sales Representative Frequency and Reach
        • Last Time of Contact with a Darzalex and Empliciti Representative
        • Time of Last Contact with Sales Representative
      • Satisfaction with Darzalex Empliciti Sales Representative
        • Sales Representative Performance
      • Darzalex Empliciti Message Recall
        • Topics Discussed by Sales Representative - Darzalex
        • Topics Discussed by Sales Representative - Empliciti
        • Education Materials Provided to Patients Prescribed Darzalex and Empliciti
        • Physicians' Comments Regarding Darzalex and Empliciti Sales Representatives
    • Methodology
    • Appendix
      • Primary Market Research Methodology
        • Physician Demographics
      • Additional Information
        • Background, Market News, Methodology, and Objectives
        • Patient Inquiries and Requests Regarding Darzalex
        • Requirements for Managed Care Approval of Darzalex and Empliciti
        • Influence of Managed Care Approval Process on Prescribing Darzalex and Empliciti
        • Patient Inquiries and Requests Regarding Empliciti
        • Denial of Darzalex Prescriptions by Patients' Managed Care Plans
        • Patient Awareness of Darzalex and Empliciti
        • Case Study #1: Patient with Multiple Myeloma Previously Prescribed Velcade + Dexamethasone (BD)
        • Case Study #2: Patient with Multiple Myeloma Quickly Progressed to Fourth Line of Therapy
        • Denial of Empliciti Prescriptions by Patients' Managed Care Plans
        • Ease of Managed Care Process for Darzalex and Empliciti
        • Common Restrictions on the Duration of Treatment for Darzalex and Empliciti
        • Awareness of Darzalex and Empliciti Profile
        • Key Reasons for Choosing to Prescribe Another Agent over Darzalex/Empliciti
        • Coordination of Dosing Schedules to Minimize Waste

Author(s): Dana Gheorghe

Dana Gheorghe, is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a in cellular biology and biochemistry from the University of Sheffield and a in Molecular Biology from the University of Edinburgh.


Related Reports

Multiple Myeloma | Geographic Focus: China | Multiple Myeloma | China In-Depth | China

MARKET OUTLOOK Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the intro...

View Details

Multiple Myeloma | Landscape & Forecast | Disease Landscape & Forecast

Market Outlook The multiple myeloma landscape is witnessing successive label expansions. The availability of premium-priced branded agents prescribed in not just doublet...

View Details

Multiple Myeloma | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK Successive label expansions in the multiple myeloma treatment landscape are driving significant commercial reward for some well-entrenched current therapi...

View Details

Multiple Myeloma | Epidemiology | Epidemiology Dashboard

DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of mu...

View Details